Bender, D. A., Nayak, S. M., Siegel, J. S., Hellerstein, D. J., Ercal, B. C., & Lenze, E. J. (2025). Psychological Support Approaches in Psychedelic Therapy. The Journal of Clinical Psychiatry, 86(1). https://doi.org/10.4088/jcp.24m15521

Wang, E., Mathai, D. S., Gukasyan, N., Nayak, S., & Garcia-Romeu, A. (2024). Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-024-78736-1

How Should We Expand Access to Psychedelics While Maintaining an Environment of Peace and Safety? (2024). AMA Journal of Ethics, 26(11), E868-874. https://doi.org/10.1001/amajethics.2024.868

Yaden, D. B., Gukasyan, N., & Nayak, S. M. (2024). Psilocybin in Bipolar II Study Provides Preliminary Data on Safety. JAMA Psychiatry, 81(6), 541. https://doi.org/10.1001/jamapsychiatry.2023.4680

Budney, A. J., Borodovsky, J. T., Struble, C. A., Habib, M. I., Shmulewitz, D., Livne, O., Aharonovich, E., Walsh, C., Cuttler, C., & Hasin, D. S. (2024). Estimating THC Consumption from Smoked and Vaped Cannabis Products in an Online Survey of Adults Who Use Cannabis. Cannabis and Cannabinoid Research, 9(2), 688–698. https://doi.org/10.1089/can.2022.0238

Aron, J. A., Healy, E. W., Robinson, J. R. M., & Blinderman, C. D. (2024). Effects of Medical Cannabis Certification on Hospital Use by Individuals with Sickle Cell Disease. Cannabis and Cannabinoid Research, 9(2), 629–634. https://doi.org/10.1089/can.2022.0136

Borodovsky, J. T., Hasin, D. S., Shmulewitz, D., Walsh, C., Livne, O., Aharonovich, E., Struble, C. A., Habib, M. I., & Budney, A. J. (2024). Typical Hits, Grams, or Joints: Evaluating Cannabis Survey Measurement Strategies for Quantifying Consumption. Cannabis and Cannabinoid Research, 9(2), 646–658. https://doi.org/10.1089/can.2022.0237

Mauro, P. M., Gutkind, S., Askari, M. S., Hasin, D. S., Samples, H., Mauro, C. M., Annunziato, E. M., Boustead, A. E., & Martins, S. S. (2024). Associations between cannabis policies and state-level specialty cannabis use disorder treatment in the United States, 2004–2019. Drug and Alcohol Dependence, 257, 111113. https://doi.org/10.1016/j.drugalcdep.2024.111113

Walsh, C. A., Gorfinkel, L., Shmulewitz, D., Stohl, M., & Hasin, D. S. (2024). Use of Lysergic Acid Diethylamide by Major Depression Status. JAMA Psychiatry, 81(1), 89. https://doi.org/10.1001/jamapsychiatry.2023.3867

Borodovsky, J. T., Struble, C. A., Habib, M. I., Hasin, D. S., Shmulewitz, D., Walsh, C., Livne, O., Aharonovich, E., & Budney, A. J. (2023). Exploring survey methods for measuring consumption quantities of cannabis flower and concentrate products. The American Journal of Drug and Alcohol Abuse, 49(6), 733–745. https://doi.org/10.1080/00952990.2023.2246635

Keyes, K. M., & Patrick, M. E. (2023). Hallucinogen use among young adults ages 19–30 in the United States: Changes from 2018 to 2021. Addiction, 118(12), 2449–2454. Portico. https://doi.org/10.1111/add.16259

Kearney-Ramos, T., Herrmann, E. S., Belluomo, I., Matias, I., Vallée, M., Monlezun, S., Piazza, P. V., & Haney, M. (2023). The Relationship Between Circulating Endogenous Cannabinoids and the Effects of Smoked Cannabis. Cannabis and Cannabinoid Research, 8(6), 1069–1078. https://doi.org/10.1089/can.2021.0185

Zhao, Y., Potenza, M. N., Tapert, S. F., & Paulus, M. P. (2023). Neural correlates of negative life events and their relationships with alcohol and cannabis use initiation. Dialogues in Clinical Neuroscience, 25(1), 112–121. https://doi.org/10.1080/19585969.2023.2252437

Hill, M. N., Haney, M., Hillard, C. J., Karhson, D. S., & Vecchiarelli, H. A. (2023). The endocannabinoid system as a putative target for the development of novel drugs for the treatment of psychiatric illnesses. Psychological Medicine, 53(15), 7006–7024. https://doi.org/10.1017/s0033291723002465

Keyes, K. M., Joseph, V., Kaur, N., Kreski, N. T., Chen, Q., Martins, S. S., Hasin, D., Olfson, M., & Mauro, P. M. (2023). Adolescent simultaneous use of alcohol and marijuana by trends in cigarette and nicotine vaping from 2000 to 2020. Drug and Alcohol Dependence, 249, 109948. https://doi.org/10.1016/j.drugalcdep.2023.109948

Chambers, J., Keyhani, S., Ling, P. M., Hoggatt, K. J., Hasin, D., Nguyen, N., Woods, A., Ryder, A., & Cohen, B. E. (2023). Perceptions of Safety of Daily Cannabis vs Tobacco Smoking and Secondhand Smoke Exposure, 2017-2021. JAMA Network Open, 6(8), e2328691. https://doi.org/10.1001/jamanetworkopen.2023.28691

Gonçalves, P. D., Bruzelius, E., Levy, N. S., Segura, L. E., Livne, O., Gutkind, S., Boustead, A. E., Hasin, D. S., Mauro, P. M., Silver, D., Macinko, J., & Martins, S. S. (2023). Recreational cannabis legislation and binge drinking in U.S. adolescents and adults. International Journal of Drug Policy, 118, 104085. https://doi.org/10.1016/j.drugpo.2023.104085

Shmulewitz, D., Budney, A. J., Borodovsky, J. T., Bujno, J. M., Walsh, C. A., Struble, C. A., Livne, O., Habib, M. I., Aharonovich, E., & Hasin, D. S. (2023). Dimensionality and differential functioning of DSM-5 cannabis use disorder criteria in an online sample of adults with frequent cannabis use. Journal of Psychiatric Research, 163, 211–221. https://doi.org/10.1016/j.jpsychires.2023.05.048

Kreski, N. T., Ankrum, H., Cerdá, M., Chen, Q., Hasin, D., Martins, S. S., Olfson, M., & Keyes, K. M. (2023). Nicotine Vaping and Co-occurring Substance Use Among Adolescents in the United States from 2017–2019. Substance Use & Misuse, 58(9), 1075–1079. https://doi.org/10.1080/10826084.2023.2188462

Haney, M., Vallée, M., Fabre, S., Collins Reed, S., Zanese, M., Campistron, G., Arout, C. A., Foltin, R. W., Cooper, Z. D., Kearney-Ramos, T., Metna, M., Justinova, Z., Schindler, C., Hebert-Chatelain, E., Bellocchio, L., Cathala, A., Bari, A., Serrat, R., Finlay, D. B., … Piazza, P. V. (2023). Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials. Nature Medicine, 29(6), 1487–1499. https://doi.org/10.1038/s41591-023-02381-w

Palamar, J. J., Le, A., Cleland, C. M., & Keyes, K. M. (2023). Trends in drug use among nightclub and festival attendees in New York City, 2017-2022. International Journal of Drug Policy, 115, 104001. https://doi.org/10.1016/j.drugpo.2023.104001

Hasin, D. S., Borodovsky, J., Shmulewitz, D., Walsh, C., Struble, C. A., Livne, O., Habib, M. I., Fink, D. S., Aharonovich, E., & Budney, A. (2023). Adult use of highly-potent Δ9-THC cannabis concentrate products by U.S. state cannabis legalization status, 2021. Addictive Behaviors, 140, 107617. https://doi.org/10.1016/j.addbeh.2023.107617

Shmulewitz, D., Stohl, M., Greenstein, E., Roncone, S., Walsh, C., Aharonovich, E., Wall, M. M., & Hasin, D. S. (2021). Validity of the DSM-5 craving criterion for alcohol, tobacco, cannabis, cocaine, heroin, and non-prescription use of prescription painkillers (opioids). Psychological Medicine, 53(5), 1955–1969. https://doi.org/10.1017/s0033291721003652

Murray, C. H., Haney, M., Foltin, R. W., Manubay, J., Bedi, G., & Cooper, Z. D. (2023). Smoked cannabis reduces peak cocaine plasma levels and subjective effects in a controlled drug administration study of polysubstance use in men. Drug and Alcohol Dependence, 243, 109757. https://doi.org/10.1016/j.drugalcdep.2022.109757

Livne, O., Shmulewitz, D., Walsh, C., & Hasin, D. S. (2022). Adolescent and adult time trends in US hallucinogen use, 2002–19: any use, and use of ecstasy, LSD and PCP. Addiction, 117(12), 3099–3109. Portico. https://doi.org/10.1111/add.15987

Henningfield, J. E., Coe, M. A., Griffiths, R. R., Belouin, S. J., Berger, A., Coker, A. R., Comer, S. D., Heal, D. J., Hendricks, P. S., Nichols, C. D., Sapienza, F., Vocci, F. J., & Zia, F. Z. (2022). Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling. Neuropharmacology, 218, 109220. https://doi.org/10.1016/j.neuropharm.2022.109220

Fink, D. S., Shmulewitz, D., Mannes, Z. L., Stohl, M., Livne, O., Wall, M., & Hasin, D. S. (2022). Construct validity of DSM-5 cannabis use disorder diagnosis and severity levels in adults with problematic substance use. Journal of Psychiatric Research, 155, 387–394. https://doi.org/10.1016/j.jpsychires.2022.09.016

Mauro, P. M., Gutkind, S., Rivera-Aguirre, A., Gary, D., Cerda, M., Santos, E. C., Castillo-Carniglia, A., & Martins, S. S. (2022). Trends in cannabis or cocaine-related dependence and alcohol/drug treatment in Argentina, Chile, and Uruguay. International Journal of Drug Policy, 108, 103810. https://doi.org/10.1016/j.drugpo.2022.103810

Livne, O., Budney, A., Borodovsky, J., Walsh, C., Shmulewitz, D., Fink, D. S., Struble, C. A., Habib, M., Aharonovich, E., & Hasin, D. S. (2022). Delta-8 THC use in US adults: Sociodemographic characteristics and correlates. Addictive Behaviors, 133, 107374. https://doi.org/10.1016/j.addbeh.2022.107374

Smith, W. R., & Appelbaum, P. S. (2022). Novel ethical and policy issues in psychiatric uses of psychedelic substances. Neuropharmacology, 216, 109165. https://doi.org/10.1016/j.neuropharm.2022.109165

Weinberger, A. H., Wyka, K., & Goodwin, R. D. (2022). Impact of cannabis legalization in the United States on trends in cannabis use and daily cannabis use among individuals who smoke cigarettes. Drug and Alcohol Dependence, 238, 109563. https://doi.org/10.1016/j.drugalcdep.2022.109563

Keyes, K. M., Kreski, N. T., Ankrum, H., Cerdá, M., Chen, Q., Hasin, D. S., Martins, S. S., Olfson, M., & Miech, R. (2022). Frequency of adolescent cannabis smoking and vaping in the United States: Trends, disparities and concurrent substance use, 2017–19. Addiction, 117(8), 2316–2324. Portico. https://doi.org/10.1111/add.15912

Weinberger, A. H., Wyka, K., Kim, J. H., Smart, R., Mangold, M., Schanzer, E., Wu, M., & Goodwin, R. D. (2022). A difference‐in‐difference approach to examining the impact of cannabis legalization on disparities in the use of cigarettes and cannabis in the United States, 2004–17. Addiction, 117(6), 1768–1777. Portico. https://doi.org/10.1111/add.15795

Philbin, M. M., Giovenco, D. P., & Mauro, P. M. (2022). Commentary on Weinberger et al.: Tobacco and cannabis policies as drivers of nicotine and cannabis co‐use ‐ research and measurement implications to move the field forward. Addiction, 117(6), 1778–1780. Portico. https://doi.org/10.1111/add.15885

Phelps, J., Shah, R. N., & Lieberman, J. A. (2022). The Rapid Rise in Investment in Psychedelics—Cart Before the Horse. JAMA Psychiatry, 79(3), 189. https://doi.org/10.1001/jamapsychiatry.2021.3972

Haney, M. (2022). Cannabis Use and the Endocannabinoid System: A Clinical Perspective. American Journal of Psychiatry, 179(1), 21–25. https://doi.org/10.1176/appi.ajp.2021.21111138

Hasin, D. S., Borodovsky, J., Shmulewitz, D., Walsh, C., Livne, O., Struble, C. A., Aharonovich, E., Fink, D. S., & Budney, A. (2021). Use of highly-potent cannabis concentrate products: More common in U.S. states with recreational or medical cannabis laws. Drug and Alcohol Dependence, 229, 109159. https://doi.org/10.1016/j.drugalcdep.2021.109159